abstract：BACKGROUND:Earlier commencement of clozapine has been related to a better response in treatment-resistant schizophrenia. OBJECTIVES:To identify variables that predict clozapine use after a first episode of schizophrenia (FES). METHODS:Patients with FES and ≤15 days of lifetime antipsychotic treatment were followed up...

journal_title：CNS drugs

authors： Üçok A,Çıkrıkçılı U,Ergül C,Tabak Ö,Salaj A,Karabulut S,Correll CU

更新日期：2016-10-01 00:00:00

abstract：:Treatment of pediatric migraine remains an unmet medical need. There continues to be a paucity of pediatric randomized controlled trials for the treatment of migraine, both in the acute and preventive settings. Pediatric studies are often complicated by high placebo-response rates and much of our current practice is b...

journal_title：CNS drugs

authors： Kacperski J,Hershey AD

更新日期：2016-09-01 00:00:00

abstract：BACKGROUND:Antidepressant-induced liver injury is a major concern and a liver monitoring scheme has been recommended by the European Medicines Agency for agomelatine. OBJECTIVE:The objective of this study was to assess the liver safety and identify the characteristics of patients who developed a significant increase i...

journal_title：CNS drugs

authors： Perlemuter G,Cacoub P,Valla D,Guyader D,Saba B,Batailler C,Moore K

更新日期：2016-09-01 00:00:00

abstract：INTRODUCTION:The gabapentinoids pregabalin and gabapentin are being increasingly prescribed for a range of clinical conditions. Recently, although gabapentinoids at therapeutic dosages may present with low addictive liability levels, cases of misuse and rising numbers of related fatalities have been reported. OBJECTIV...

journal_title：CNS drugs

authors： Chiappini S,Schifano F

更新日期：2016-07-01 00:00:00

abstract：:Secondary progressive multiple sclerosis (SPMS) is diagnosed retrospectively and involves a clinical course characterized by a progressive accumulation of neurological disability, independent of relapses, following an initial relapsing-remitting (RR) phase. Our incomplete understanding of the pathological mechanisms u...

journal_title：CNS drugs

authors： Plantone D,De Angelis F,Doshi A,Chataway J

更新日期：2016-06-01 00:00:00

abstract：:Narcolepsy type 1 and narcolepsy type 2 are central disorders of hypersomnolence. Narcolepsy type 1 is characterized by excessive daytime sleepiness and cataplexy and is associated with hypocretin-1 deficiency. On the other hand, in narcolepsy type 2, cerebrospinal fluid hypocretin-1 levels are normal and cataplexy ab...

journal_title：CNS drugs

authors： Barateau L,Lopez R,Dauvilliers Y

更新日期：2016-05-01 00:00:00

abstract：BACKGROUND:Responses to atomoxetine vary for individual patients with attention-deficit/hyperactivity disorder (ADHD). However, we do not know whether any factors can be used to reliably predict how individuals with ADHD will respond to treatment. OBJECTIVE:Our objective was to evaluate background variables that facil...

journal_title：CNS drugs

authors： Bushe C,Sobanski E,Coghill D,Berggren L,De Bruyckere K,Leppämäki S

更新日期：2016-04-01 00:00:00

abstract：:Lisdexamfetamine dimesylate (lisdexamfetamine) is a long-acting amfetamine prodrug with a convenient once-daily oral regimen that offers the potential for improved adherence and reduced abuse compared with short-acting preparations of amfetamines. Lisdexamfetamine (as Elvanse Adult(®); Tyvense Adult™) has been approve...

journal_title：CNS drugs

authors： Frampton JE

更新日期：2016-04-01 00:00:00

abstract：:Progress in finding a better alternative to alteplase has been slow. Tenecteplase and desmoteplase have better pharmacological profiles compared with alteplase, but definite clinical evidence of their superiority is lacking. The two major phase III studies that have tested the efficacy and safety of desmoteplase in is...

journal_title：CNS drugs

authors： Logallo N,Kvistad CE,Nacu A,Thomassen L

更新日期：2016-02-01 00:00:00

abstract：INTRODUCTION:Valproic acid is a versatile antiepileptic drug that is often used in the acute care setting. Intravenous valproic acid lends itself well to a continuous infusion as it exhibits a relatively short half-life. We evaluated the pharmacokinetics and clinical efficacy of continuous infusion valproic acid in hos...

journal_title：CNS drugs

authors： Cook AM,Zafar MS,Mathias S,Stewart AM,Albuja AC,Bensalem-Owen M,Kapoor S,Baumann RJ

更新日期：2016-01-01 00:00:00

abstract：:Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). More recently (September 2014), the EU summary of product characteristics (SmPC) was updated to include data from patients with a first cli...

journal_title：CNS drugs

authors： Chan A,de Seze J,Comabella M

更新日期：2016-01-01 00:00:00

abstract：:The link between diabetes mellitus and Alzheimer's disease (AD) has been known for the last few decades. Since insulin and insulin receptors are known to be present in the brain, the downstream signalling as well as the effect of hyperinsulinemia have been extensively studied in both AD and Parkinson's disease. Glucag...

journal_title：CNS drugs

authors： Calsolaro V,Edison P

更新日期：2015-12-01 00:00:00

abstract：:How a woman responds to sexual cues is highly dependent on a number of distinct, yet related, factors. Researchers have attempted to explain the female sexual response for decades, but no single model reigns supreme. Proper female sexual function relies on the interplay of somatic, psychosocial and neurobiological fac...

journal_title：CNS drugs

authors： Kingsberg SA,Clayton AH,Pfaus JG

更新日期：2015-11-01 00:00:00

abstract：:Several studies have found a correlation between the presence of circulating maternal autoantibodies and neuronal dysfunction in the neonate. Specifically, maternal anti-brain autoantibodies, which may access the fetal compartment during gestation, have been identified as one risk factor for developing autism spectrum...

journal_title：CNS drugs

authors： Fox-Edmiston E,Van de Water J

更新日期：2015-09-01 00:00:00

abstract：:Alzheimer's disease (AD) is frequently associated with neuropsychiatric symptoms (NPS) such as agitation and aggression, especially in the moderate to severe stages of the illness. The limited efficacy and high-risk profiles of current pharmacotherapies for the management of agitation and aggression in AD have driven ...

journal_title：CNS drugs

authors： Liu CS,Chau SA,Ruthirakuhan M,Lanctôt KL,Herrmann N

更新日期：2015-08-01 00:00:00

abstract：:Restless legs syndrome (RLS) is a common, frequently chronic, sensorimotor neurological disorder characterized by nocturnal leg dysesthesias and an irresistible urge to move the legs, usually resulting in sleep disturbance. Dopaminergic agonists, alpha-2-delta calcium-channel ligands, and opioids have all demonstrated...

journal_title：CNS drugs

authors： Mackie S,Winkelman JW

更新日期：2015-05-01 00:00:00

abstract：:Alcoholic patients suffer from harmful allostatic neuroplastic changes in the brain causing an acute withdrawal syndrome upon cessation of drinking followed by a protracted abstinence syndrome and an increased risk of relapse to heavy drinking. Benzodiazepines have long been the treatment of choice for detoxifying pat...

journal_title：CNS drugs

authors： Hammond CJ,Niciu MJ,Drew S,Arias AJ

更新日期：2015-04-01 00:00:00

abstract：:Much work has been carried out in recent years showing that elevated glutamate levels in the extracellular environment of the central nervous system play a pivotal role in neurodegeneration in acute CNS injuries. With the elucidation of the mechanism governing glutamate excitotoxicity, researchers are devising therape...

journal_title：CNS drugs

authors： Jia M,Njapo SA,Rastogi V,Hedna VS

更新日期：2015-02-01 00:00:00

abstract：PURPOSE:To monitor weight regain after therapy discontinuation in patients with migraine experiencing weight loss during topiramate (TPM) treatment. METHODS:Patients with migraine without aura were enrolled in this observational prospective study. Weight, body mass index (BMI), waist circumference, systolic and diasto...

journal_title：CNS drugs

authors： Verrotti A,Parisi P,Agostinelli S,Loiacono G,Marra F,Coppola G,Pisani LR,Gorgone G,Striano P,Pisani F,Belcastro V

更新日期：2015-02-01 00:00:00

abstract：INTRODUCTION:Intranasal (IN) insulin acutely improves verbal memory in mild cognitive impairment (MCI)/Alzheimer's disease (AD), but its therapeutic effects may be attenuated in apolipoprotein E4 (ApoE4) carriers. Furthermore, rapid-acting (RA) insulins may have superior therapeutic effects compared with regular insuli...

journal_title：CNS drugs

authors： Rosenbloom MH,Barclay TR,Pyle M,Owens BL,Cagan AB,Anderson CP,Frey WH 2nd,Hanson LR

更新日期：2014-12-01 00:00:00

abstract：:L-Dopa-induced dyskinesias (LID) are the most common adverse effects of long-term dopaminergic therapy in Parkinson's disease (PD). However, the exact mechanisms underlying dyskinesia are still unclear. For a long time, nigrostriatal degeneration and pulsatile stimulation of striatal postsynaptic receptors have been h...

journal_title：CNS drugs

authors： Schaeffer E,Pilotto A,Berg D

更新日期：2014-12-01 00:00:00

abstract：BACKGROUND:Few studies examine predictors of seizures in medically treated patients with epilepsy receiving antiepileptic monotherapy using a large patient population. OBJECTIVE:Our objective was to identify clinical, medication, and demographic factors associated with seizure recurrence in medically treated patients ...

journal_title：CNS drugs

authors： Shcherbakova N,Rascati K,Brown C,Lawson K,Novak S,Richards KM,Yoder L

更新日期：2014-11-01 00:00:00

abstract：:Diclofenac potassium powder for oral solution (Voltfast(®), Catafast(®), Cambia(®); hereafter referred to as diclofenac potassium powder) is a non-steroidal anti-inflammatory drug (NSAID), and is indicated for the acute treatment of migraine. This article reviews the pharmacological properties of diclofenac potassium ...

journal_title：CNS drugs

authors： Garnock-Jones KP

更新日期：2014-08-01 00:00:00

abstract：:All current antipsychotic drugs block dopamine (DA) receptors, but the nature of the DA dysfunction in schizophrenia has not been clear. However, consistent evidence now shows that presynaptic dopaminergic function is altered in schizophrenia, specifically in terms of increased DA synthesis capacity, baseline synaptic...

journal_title：CNS drugs

authors： Bonoldi I,Howes OD

更新日期：2014-07-01 00:00:00

abstract：OBJECTIVE:This study examines the effects of parental lisdexamfetamine (LDX) treatment on parent-child interactions. METHODS:Participants were 30 parents (27% were male) and their children aged 5-12 years, both diagnosed with DSM-IV attention-deficit/hyperactivity disorder (ADHD). Optimal LDX dose (30, 50, or 70 mg/da...

journal_title：CNS drugs

authors： Waxmonsky JG,Waschbusch DA,Babinski DE,Humphrey HH,Alfonso A,Crum KI,Bernstein M,Slavec J,Augustus JN,Pelham WE

更新日期：2014-07-01 00:00:00

abstract：:Evidence-based treatment approaches for generalized anxiety disorder (GAD) comprise psychotherapy, pharmacotherapy, or a combination of the two. First-line pharmacotherapy agents include selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, and, in certain European guidelines...

journal_title：CNS drugs

authors： Hershenberg R,Gros DF,Brawman-Mintzer O

更新日期：2014-06-01 00:00:00

abstract：:The demonstrated benefits of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) for cardiovascular and cerebrovascular disease are well established in the medical literature, and this class of medications is among those most commonly prescribed in the USA. In 2012, the US Food and Drug Admi...

journal_title：CNS drugs

authors： Kelley BJ,Glasser S

更新日期：2014-05-01 00:00:00

abstract：:Statins, or 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, such as lovastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, rosuvastatin and pitavastatin, are cholesterol-lowering drugs used in clinical practice to prevent coronary heart disease. These drugs are generally well tolerated and have ...

journal_title：CNS drugs

authors： Tuccori M,Montagnani S,Mantarro S,Capogrosso-Sansone A,Ruggiero E,Saporiti A,Antonioli L,Fornai M,Blandizzi C

更新日期：2014-03-01 00:00:00

abstract：:Aripiprazole (Abilify(®)) is an atypical antipsychotic that is widely used in the treatment of psychiatric conditions. Unlike other currently available atypical antipsychotics that primarily have varying degrees of dopamine D2 receptor antagonism, aripiprazole is a partial agonist at D2 and serotonin 5-HT1A receptors,...

journal_title：CNS drugs

authors： McKeage K

更新日期：2014-02-01 00:00:00

abstract：:Attention-deficit/hyperactivity disorder, or ADHD, is the most frequently occurring neurobiological disorder in childhood and is defined by symptoms of inattention and/or hyperactivity and impulsivity that are excessive when compared with other individuals at the same developmental level. ADHD can be successfully trea...

journal_title：CNS drugs

authors： Childress AC,Sallee FR

更新日期：2014-02-01 00:00:00

abstract：:Lacosamide (Vimpat(®)) is a functionalized amino acid available orally (as a syrup or tablet) and as an intravenous infusion. It is believed to exert its antiepileptic effect by selectively enhancing the slow inactivation of voltage-gated sodium channels. Lacosamide is approved in several countries worldwide as an adj...

journal_title：CNS drugs

authors： Hoy SM

更新日期：2013-12-01 00:00:00

abstract：BACKGROUND:No head-to-head clinical trials have been published comparing guanfacine extended release (GXR) and atomoxetine (ATX): two nonstimulants approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). However, other study designs or methods could be used to indirectly compare these two medicat...

journal_title：CNS drugs

authors： Sikirica V,Findling RL,Signorovitch J,Erder MH,Dammerman R,Hodgkins P,Lu M,Xie J,Wu EQ

更新日期：2013-11-01 00:00:00

abstract：:Naltrexone is a μ-opioid receptor antagonist that blocks the euphoric effects of heroin and prescription opioids. In order to improve treatment adherence, a once-monthly, intramuscular, extended-release formulation of naltrexone (XR-NTX) [VIVITROL(®)] has been developed, and approved in the USA and Russia for the prev...

journal_title：CNS drugs

authors： Syed YY,Keating GM

更新日期：2013-10-01 00:00:00

abstract：:Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that is pathologically characterized by inflammatory demyelination and neurodegeneration. Axonal damage, along with neuronal loss, occurs from disease onset and may lead to progressive and permanent disability. In contrast with the inflam...

journal_title：CNS drugs

authors： Maghzi AH,Minagar A,Waubant E

更新日期：2013-10-01 00:00:00

abstract：:Down syndrome (DS), which results from an extra copy of chromosome 21 (trisomy 21), is the most common genetically defined cause of intellectual disability. Although no pharmacotherapy aimed at counteracting the cognitive and adaptive deficits associated with this genetic disorder has been approved at present, there h...

journal_title：CNS drugs

authors： Costa AC,Scott-McKean JJ

更新日期：2013-09-01 00:00:00

abstract：:Loxapine is a well-established, first-generation antipsychotic agent. Loxapine inhalation powder (Adasuve(®)) was recently approved in the USA and the EU for use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. Inhaled loxapine is delivered by a hand-held, single-dose, single-use...

journal_title：CNS drugs

authors： Keating GM

更新日期：2013-06-01 00:00:00

abstract：:Major depressive disorder (MDD) is a chronic, recurrent mental disease that causes serious disability. Because currently available antidepressants have limited efficacy with respect to response and remission in patients with MDD, clinicians must choose the best available treatment interventions for patients who do not...

journal_title：CNS drugs

authors： Pae CU,Patkar AA

更新日期：2013-05-01 00:00:00

abstract：BACKGROUND:Refractory status epilepticus (RSE) is an emergency with high mortality requiring neurointensive care. Treatment paradigms include first-generation antiepileptic drugs (AEDs) and anesthetics. Lacosamide (LCM) is a new AED, holding promise as a potent treatment option for RSE. High-level evidence regarding sa...

journal_title：CNS drugs

authors： Sutter R,Marsch S,Rüegg S

更新日期：2013-04-01 00:00:00

abstract：:Epileptic encephalopathy is defined as a condition where the epileptic activity itself may contribute to the severe neurological and cognitive impairment seen, over and above that which would be expected from the underlying pathology alone. The epilepsy syndromes at high risk of this are a disparate group of condition...

journal_title：CNS drugs

authors： McTague A,Cross JH

更新日期：2013-03-01 00:00:00

abstract：BACKGROUND:There is growing epidemiological evidence that opioids may increase the risk of unintentional injuries and it is plausible that the time of initiation is most critical in that respect. Studies on fall-related injuries remain few, limited and mostly focused on specific groups of elderly patients. OBJECTIVE:T...

journal_title：CNS drugs

authors： Söderberg KC,Laflamme L,Möller J

更新日期：2013-02-01 00:00:00